KLTO Stock Overview
A biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Klotho Neurosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.34 |
| 52 Week High | US$13.10 |
| 52 Week Low | US$0.26 |
| Beta | 0.056 |
| 11 Month Change | -38.07% |
| 3 Month Change | -66.34% |
| 1 Year Change | -96.82% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| KLTO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.03% | 4.3% | 1.6% |
| 1Y | -96.8% | 18.8% | 32.3% |
Return vs Industry: KLTO underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: KLTO underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| KLTO volatility | |
|---|---|
| KLTO Average Weekly Movement | 20.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KLTO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KLTO's weekly volatility has decreased from 30% to 21% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1 | Joe Sinkule | www.klothoneuro.com |
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.
Klotho Neurosciences, Inc. Fundamentals Summary
| KLTO fundamental statistics | |
|---|---|
| Market cap | US$6.98m |
| Earnings (TTM) | -US$4.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs KLTO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KLTO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.21m |
| Earnings | -US$4.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KLTO perform over the long term?
See historical performance and comparison